Search Results
Your search for The ASCO matches 20656 pages
Showing 401 - 450Machine-Learning Model May Aid in Early Diagnosis of Hepatocellular Carcinoma
A serum fusion-gene machine-learning model may offer early diagnostic accuracy and could help improve the 5-year survival rate in patients with hepatocellular carcinoma, according to a recent study published by Yu et al in The American Journal of Pathology. Background Hepatocellular carcinoma is...
Phase I Study in NHL: Use of ‘Armored’ CAR T Cells May Be Feasible After Standard CAR T-Cell Failure
A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond to standard CAR T-cell therapy, according to preliminary results of a phase I trial presented at the 2024 ASCO Annual Meeting.1 The unique...
Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer
Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...
Can FAP-Targeted Radioligand Therapy Benefit Patients With Advanced Sarcomas?
Fibroblast activation protein (FAP)-targeted radioligand therapy may be safe and effective in patients with progressive metastatic tumors, particularly advanced sarcomas, according to new findings presented by Lanzafame et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI)...
FAPI PET/CT May Improve Staging in Newly Diagnosed Breast Cancer
Researchers have found that fibroblast activation protein inhibitor (FAPI) positron-emission tomography/computed tomography (PET/CT) may offer more accurate staging in patients with newly diagnosed breast cancer than fluorine (F)-18–labeled fluorodeoxyglucose (FDG) PET/CT, according to new findings ...
FDA Approves Blinatumomab as Consolidation for CD19-Positive, Ph-Negative B-Cell Precursor ALL
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto) for adult and pediatric patients aged 1 month and older with CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of...
FDA Approves Two Immunochemotherapy Combinations for Endometrial Cancer
On June 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by single-agent pembrolizumab for adult patients with primary advanced or recurrent endometrial carcinoma; on June 14, the agency approved durvalumab...
Chelating Agent May Reduce Toxicity Associated With PSMA Radiopharmaceutical Therapy
A novel chelator may significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to new findings presented by Ho et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 242340). Background...
Pretargeted Dual-Isotope Radionuclide Therapy in Colorectal Cancer
A combination of alpha- and beta-radionuclide therapy may be feasible, tolerable, and effective in colorectal cancer, according to preclinical findings presented by Rinne et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 241498). The new approach...
Using a Novel AI Tool for Cancer Detection on Whole-Body PET/CT Scans
A novel artificial intelligence (AI) tool may accurately detect six different types of cancers on whole-body positron-emission tomography/computed tomography (PET/CT) scans and automatically quantify tumor burden to assess patient risk, treatment response, and survival, according to new findings...
Lenalidomide-Exposed Relapsed or Refractory Multiple Myeloma: BPd vs PVd
As reported at the 2024 ASCO Annual Meeting (Abstract LBA105) and in The New England Journal of Medicine by Meletios Dimopoulos, MD, and colleagues, an interim analysis from the phase III DREAMM-8 trial has shown significantly improved progression-free survival with belantamab mafodotin-blmf,...
Mobile Monitoring System May Improve Detection of Ethylene Oxide in Louisiana’s ‘Cancer Alley’
Measuring ethylene oxide levels using mobile optical instruments in Louisiana’s southeastern corridor may help to improve cancer risk assessments, according to a recent study published by Robinson et al in Environmental Science & Technology. Background Louisiana’s southeastern corridor is...
FDA Grants Accelerated Approval to Repotrectinib for NTRK Fusion–Positive Solid Tumors
On June 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or...
V. Craig Jordan, PhD, a Founding Father of Targeted Therapy in Cancer, Dies at Age 76
Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact the field for generations to come, died on June 9, according to a news release from The University of Texas MD Anderson Cancer...
Can Positive Psychology Influence Outcomes in Hematopoietic Stem Cell Transplantation Recipients?
A novel positive psychology approach may help improve stress, fatigue, physical function, and quality of life in patients with hematologic malignancies who undergo hematopoietic stem cell transplantation, according to a new study published by Amonoo et al in JNCCN–Journal of the National...
Drug Resistance in Melanoma-Related Leptomeningeal Disease
Researchers uncovered potential mechanisms driving drug resistance in patients with melanoma and leptomeningeal disease, according to a recent study published by Alhaddad et al in Cell Reports Medicine. Background Leptomeningeal disease is a rare and often lethal complication experienced by about...
FDA Approves Selpercatinib for RET Fusion–Positive Thyroid Cancer
On June 12, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and whose disease is radioactive...
How Often Do Patients With Cancer Face Barriers When Attempting to Access Care?
Many patients with cancer encounter significant barriers to the receipt of care, according to a recent study published by Chen et al in JAMA Network Open. Background When attempting to access cancer care, patients often must go through several different levels of communication both before their...
Lung Cancer Screening May Improve Early Detection, Survival in U.S. Veterans
Investigators have found that U.S. veterans who underwent lung cancer screening prior to diagnosis were potentially more likely to be diagnosed with earlier-stage disease and have a higher cure rate compared with those who did not undergo screening, according to a recent study published by Edwards...
Newly Diagnosed Patients With Multiple Myeloma Ineligible for Transplant: Addition of Isatuximab to VRd
As reported at the 2024 ASCO Annual Meeting (Abstract 7500) and in The New England Journal of Medicine by Thierry Facon, MD, and colleagues, interim analysis of the phase III IMROZ trial showed significantly improved progression-free survival with the addition of isatuximab to bortezomib,...
Novel Gamma-Delta T Cell–Based Therapy Plus Temozolomide Maintenance in Glioblastoma Multiforme
The novel therapy INB-200 in combination with concomitant temozolomide may improve survival in patients with glioblastoma multiforme, according to preliminary findings from a phase I clinical trial presented by Lobbous et al at the 2024 ASCO Annual Meeting (Abstract 2042). “For far too long, there...
Integrating Palliative Care Education Into Hematology-Oncology Fellowships
An integrated palliative care rotation for hematology-oncology fellows may improve their palliative care knowledge and skill confidence, according to findings presented by Bauman et al at the 2024 ASCO Annual Meeting (Abstract 9007). “Despite national guidelines advocating that patients with...
Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI
Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more...
More on Using AI to Enhance Cancer Care
I read with interest the excellent article by Anant Madabhushi, PhD, and Jame Abraham, MD, FACP, in the May 10, 2024, issue of The ASCO Post, entitled “AI in Cancer Care: Embrace the Change.” I wanted to add information on how an available AI Cancer Mentor application (app) has become a beneficial...
Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool
Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI,...
Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma
An ASCO guideline update offers new recommendations on systemic treatment for advanced hepatocellular carcinoma (HCC), based on promising findings from several recent randomized controlled trials as well as the approval of new first- and second-line immunotherapy combinations.1 “This guideline...
FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team,...
I Am Living With Recurring Stage IV Colorectal Cancer
Despite urgings from my primary care physician to get a colonoscopy screening after I turned 50, I resisted. As a health-care provider, and someone who is tuned into changes in my body, I thought I would instinctively know if I had a serious illness. I was wrong. Even after finally relenting to at...
In Celebration of a Remarkable Life and Career in Oncology
When Jamie H. Von Roenn, MD, FASCO, graduated from high school in 1970 and enrolled at the University of Illinois in Champaign, she was determined to seek a career in special education, because she wanted to “help people through difficult situations.” Although Dr. Von Roenn ultimately decided to...
Multiple Myeloma Survivor and Advocate Shares 12-Step Program: How Not to Die of Cancer
Facing mortality can be a paralyzing experience for some people, but for others, it may ignite a passion to accelerate life. One such person is Kathy Giusti, cofounder of the Multiple Myeloma Research Foundation (MMRF), where she served as Chief Executive Officer and President for nearly 20 years....
How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life
Several years ago, a visit to the National Air and Space Museum in Washington, DC, so fascinated and inspired Mace L. Rothenberg, MD, FASCO, about the history of flight, he wondered why there was not a similar museum showcasing the past and present achievements in science and medicine. The result...
NADINA Trial Shows Robust Benefit for Neoadjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma
Results of the phase III NADINA trial support a new standard of care for the treatment of resectable macroscopic stage III melanoma. Treatment with preoperative ipilimumab plus nivolumab followed by total lymph node dissection, with adjuvant therapy guided by depth of response, led to a highly...
Pancreatic Surgeon Named New Director of Moores Cancer Center at UC San Diego Health
Following an extensive national search, Diane M. Simeone, MD, has been appointed Director of Moores Cancer Center at the University of California (UC) San Diego Health. Dr. Simeone brings institutional, national, and international leadership experience both to oncologic patient care and scientific...
Cardiotoxicity: How Far Have We Come?
A little more than 12 months ago, the first major cardio-oncology guidelines were published by the European Society of Cardiology (ESC).1 The extensive document embodied the immense progress of this subspecialty over its short existence. In reaching this milestone, it is worth considering what...
Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC
Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemoradiotherapy. These findings of the phase III LAURA trial suggest that osimertinib may become a new...
FDA Approves Imetelstat for Patients With Low- to Intermediate-1 Risk MDS and Transfusion-Dependent Anemia
On June 6, 2024, the U.S. Food and Drug Administration (FDA) approved imetelstat (Rytelo), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks...
Can Pembrolizumab Improve Outcomes in Soft-Tissue Sarcoma?
The PD-1 inhibitor pembrolizumab may offer benefit in patients with soft-tissue sarcoma, according to recent findings presented by Mowery et al at the 2024 ASCO Annual Meeting (Abstract 11504). Background Soft-tissue sarcoma is a rare type of cancer affecting muscles, fat, and other connective...
Addition of Chemoradiation to Adjuvant Systemic Therapy: Differences in Node-Negative vs Node-Positive Pancreatic Cancer
Researchers have examined whether adding chemoradiation to adjuvant systemic therapy may improve survival outcomes in patients with resected periampullary pancreatic adenocarcinoma, according to recent findings presented by Abrams et al at the 2024 ASCO Annual Meeting (Abstract 4005). Study Methods ...
Study Identifies Subset of Patients With Lung Adenocarcinoma Who Have HER2 Alterations
Researchers have found that about 6% of patients with non–small cell lung cancer (NSCLC) and KRAS, EGFR, or ALK gene mutations may also have HER2 alterations, according to recent findings presented by Dahake et al at the 2024 ASCO Annual Meeting (Abstract 8534). Background Lung adenocarcinoma is...
Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone
Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free...
Proton Therapy vs Traditional Radiation Therapy in Patients With Oropharyngeal Cancer
Intensity-modulated proton therapy may achieve similar clinical outcomes and offer significant benefits compared with traditional intensity-modulated radiation therapy in patients with oropharyngeal cancer, according to preliminary data from a multi-institutional phase III trial presented by Frank...
Study Finds Early Menopause May Be Linked to Greater Risk of Breast and Ovarian Cancers
The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...
Neoadjuvant Pembrolizumab May Improve Outcomes in Some Patients With Colorectal Cancer Surgery
Researchers examined whether the PD-1 inhibitor pembrolizumab given neoadjuvantly may improve outcomes in certain patients with stage II or III mismatch repair–deficient/microsatellite instability–high colorectal cancer. Interim findings from the phase II NEOPRISM-CRC clinical trial were presented...
Chemotherapy Administration and Survival in Patients With Very Advanced Solid Tumors
In a study reported in JAMA Oncology, Canavan et al found no differences in overall survival between oncology practices that were more vs less likely to provide chemotherapy within the last 2 weeks of life to patients with very advanced solid tumors. As stated by the investigators, “ASCO and the...
Dennis J. Slamon, MD, PhD, Awarded 2024 Szent-Györgyi Prize for Progress in Cancer Research
The National Foundation for Cancer Research (NFCR) announced that the blue-ribbon selection committee, composed of world-renowned research leaders and visionaries, has awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research to Dennis J. Slamon, MD, PhD, of UCLA Health, for his...
New Study Highlights Benefits of Stepped Palliative Care in Advanced Lung Cancer
Researchers have shown the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings published by Temel et al in JAMA and simultaneously presented at the 2024 ASCO Annual Meeting (Abstract 12000). Background More intensive...
Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women
High blood insulin levels may contribute to worse outcomes in Black women with triple-negative breast cancer compared with White women with the disease, according to new findings presented by Engel et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Background Triple-negative...
Stress Related to Residing in Violent Neighborhoods May Be Tied to Aggressive Lung Cancer in Black Men
Exposure to increased neighborhood violence may change the glucocorticoid receptor for the stress hormone cortisol and influence the aggressiveness of lung cancer, according to new findings presented by Heath et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Study Methods and...
Many Breast Cancer Survivors May Experience Excess Weight Gain
Nearly 20% of breast cancer survivors may experience weight gain of more than 10%, according to recent findings presented by Hurtado Andrade et al at the Endocrine Society’s Annual Meeting & Exposition 2024. The research may illuminate a number of factors potentially contributing to excessive...
Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010). Background Circulating...
